Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors

Medientyp: E-Artikel
Titel: Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors
Beteiligte: Kratochwil, Clemens [Verfasser:in]; Giesel, Frederik L. [Verfasser:in]; López-Benítez, Ruben [Verfasser:in]; Schimpfky, Nadine [Verfasser:in]; Kunze, Kirsten [Verfasser:in]; Eisenhut, Michael [Verfasser:in]; Kauczor, Hans-Ulrich [Verfasser:in]; Haberkorn, Uwe [Verfasser:in]
Erschienen: 05/11/2010
Erschienen in: Clinical cancer research ; 16(2010), 10, Seite 2899-2905
Sprache: Englisch
DOI: 10.1158/1078-0432.CCR-10-0004
Identifikator:

Entstehung:
Anmerkungen:
Beschreibung: Therapy with the somatostatin analogue DOTA-(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) labeled with a β-(DOTA-Phe-Tyr-Octreotide) emitter such as 90Y or 177Lu is accepted for the palliative treatment of unresectable neuroendocrine cancer. However, the optimal route of administration has not been determined. Using positron-emission tomography (PET)-labeled 68Ga-DOTATOC, we compared selective tumoral uptake on PET/computed tomography (CT) after arterial or venous administration of the agent in patients with gastroenteropancreatic neuroendocrine tumor.
Zugangsstatus: Freier Zugang

Nur in Feld suchen: